DECREASE IN ACROMEGALY-ASSOCIATED THYROID ENLARGEMENT AFTER NORMALIZATION OF IGF-1 LEVELS: A PROSPECTIVE OBSERVATION AND IN VITRO STUDY
DECREASE IN ACROMEGALY-ASSOCIATED THYROID ENLARGEMENT AFTER NORMALIZATION OF IGF-1 LEVELS: A PROSPECTIVE OBSERVATION AND IN VITRO STUDY
复制标题
Igf-1 水平正常化后肢端肥大症相关的甲状腺肿大减少：前瞻性观察和体外研究
DOI：
10.4158/ep-2019-0353
复制
发表时间：
2020-04-01
影响因子：
4.2
通讯作者：
Wang, Haijun
中科院分区：
文献类型：
--
作者：
Chen, Zhiyong;Jiang, Xiaobing;Wang, Haijun
目的：甲状腺肿在肢端肥大症患者中发生率较高。胰岛素样生长因子1（IGF-1）水平的正常化是否可以减少甲状腺肿和甲状腺体积仍不清楚。方法：甲状腺激素水平和超声测量进行了评估，在101肢端肥大症患者，与108例无功能垂体腺瘤（NFPA）和55名健康对照。34例肢端肥大症患者在经蝶窦手术后1年接受了重复评价。结果：肢端肥大症患者甲状腺体积明显大于非肢端肥大症患者（18.32 mL vs.9.91 mL; P
Objective: Goiter occurs at high frequency in acromegaly patients. Whether normalization of insulin-like growth factor 1 (IGF-1) levels could decrease goiter and thyroid volume remains unclear.Methods: Thyroid hormone levels and ultrasound measurements were assessed in 101 acromegaly patients, compared with 108 patients with nonfunctioning pituitary adenoma (NFPA) and 55 healthy controls. Thirty-four acromegaly patients underwent repeat evaluation 1 year post-transsphenoidal surgery. The effect of IGF-1 on thyroid cell proliferation, cell cycle, and apoptosis was evaluated in vitro.Results: Acromegaly patients showed larger thyroid volume than those with NFPAs (18.32 mL vs. 9.91 mL; P